Kenneth J. Bender, PharmD, MA


Olanzapine/Fluoxetine Combination Affirmed for Bipolar Depression

July 17, 2013

A recent meta-analysis supports evidence of the effectiveness of the fixed olanzapine/fluoxetine combination (Symbyax) in treating the depressive phase of bipolar disorder. Response was ranked higher, but with no more adverse effects, than with treatment with olanzapine alone.

“PRN” Medication for Alcohol Dependence May Reduce Harm

June 18, 2013

In a new study, "as needed" use of an opioid antagonist for heightened alcohol craving appeared to reduce the number of heavy drinking days and total amount of alcohol consumed.

No Mortality Increase With Antipsychotics in Prospective Study

June 17, 2013

Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.

Irreversible Monoamine Oxidase Inhibitors Revisited

October 08, 2012

Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.

Refeeding Regimens for Anorexia Challenged

February 09, 2012

A new study examining conventional “start low, go slow” nutrition replenishment protocols for hospitalized patients with anorexia nervosa (AN) that have been recommended by professional organizations and it's outcomes.